Biohaven Pharmaceutical Holding Operating Income 2016-2022 | BHVN

Biohaven Pharmaceutical Holding annual/quarterly operating income history and growth rate from 2016 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Biohaven Pharmaceutical Holding operating income for the quarter ending March 31, 2022 was $-0.054B, a 77.16% decline year-over-year.
  • Biohaven Pharmaceutical Holding operating income for the twelve months ending March 31, 2022 was $-0.522B, a 28.48% decline year-over-year.
  • Biohaven Pharmaceutical Holding annual operating income for 2021 was $-0.704B, a 9.09% increase from 2020.
  • Biohaven Pharmaceutical Holding annual operating income for 2020 was $-0.645B, a 34.7% increase from 2019.
  • Biohaven Pharmaceutical Holding annual operating income for 2019 was $-0.479B, a 113.37% increase from 2018.
Biohaven Pharmaceutical Holding Annual Operating Income
(Millions of US $)
2021 $-704
2020 $-645
2019 $-479
2018 $-225
2017 $-108
2016 $-61
2015 $-10
Biohaven Pharmaceutical Holding Quarterly Operating Income
(Millions of US $)
2022-03-31 $-54
2021-12-31 $-157
2021-09-30 $-140
2021-06-30 $-172
2021-03-31 $-236
2020-12-31 $-171
2020-09-30 $-163
2020-06-30 $-161
2020-03-31 $-151
2019-12-31 $-135
2019-09-30 $-90
2019-06-30 $-199
2019-03-31 $-54
2018-12-31 $-48
2018-09-30 $-55
2018-06-30 $-38
2018-03-31 $-83
2017-12-31 $-28
2017-09-30 $-40
2017-06-30 $-25
2017-03-31 $-14
2016-12-31 $-23
2016-09-30 $-28
2016-06-30 $-7
2016-03-31 $-3
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.057B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00